DIA Biosimilars 2013

Clinical Intelligence

NinePoint Medical initiates trial of imaging system for esophagus

Tuesday, March 6, 2012 06:10 AM

NinePoint Medical, a developer of medical devices for in vivo pathology, has initiated a clinical trial to evaluate high-resolution optical imaging of Barrett’s esophagus using its proprietary Nvision VLE Imaging System, which received 510(k) clearance from the FDA earlier this year.

More... »

Cenduit: Now with Patient Reminders

OncoGenex reports promising preclinical cancer data

Monday, March 5, 2012 06:09 AM

OncoGenex Pharmaceuticals’ compound OGX-427 shows potential for augmenting anti-cancer therapies and delay tumor progression.

More... »

CRF Health – eCOA Forum

Three studies show positive results in overactive bladder

Friday, March 2, 2012 06:06 AM

Astellas Pharma Europe, subsidiary of Tokyo-based Astellas Pharma, has reported results from three separate clinical trials that further support the efficacy and tolerability of mirabegron for overactive bladder (OAB).

More... »

Nektar releases positive proof-of-concept data for opioid molecule NKTR-181

Thursday, March 1, 2012 06:02 AM

Nektar Therapeutics has reported positive clinical data for NKTR-181, its new oral opioid analgesic molecule.

More... »

Oncolytics Biotech launches phase II study in prostate cancer

Tuesday, February 28, 2012 06:08 AM

Calgary, Cananda-based Oncolytics Biotech has collaborated with the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, to conduct a randomized phase II study of Reolysin in patients with recurrent or metastatic castration resistant prostate cancer.

More... »

First vaccine for fatal visceral leishmaniasis enters clinical trial

Monday, February 27, 2012 10:08 AM

Seattle-based nonprofit Infectious Disease Research Institute (IDRI) has teamed up with India-based Gennova Biopharmaceuticals to target visceral leishmaniasis (VL), launching a phase I trial of vaccine for the infection disease.

More... »

FDA approves first drug-eluting coronary stents

Monday, February 27, 2012 10:06 AM

The FDA has approved Boston Scientific’s Ion Paclitaxel-Eluting Platinum Chromium Coronary Stent System and Taxus Liberte Paclitaxel-Eluting Coronary Stent System for use in patients experiencing an acute myocardial infarction (AMI), or heart attack. 

More... »

Onyx completes enrollment for phase III trial

Monday, February 27, 2012 10:04 AM

San Francisco, Calif.-based Onyx Pharmaceuticals has reached the target enrollment in the ASPIRE trial, a phase III international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid) and low-dose dexamethasone in patients with relapsed multiple myeloma. 

More... »

FDA advisory committee recommends Qnexa for approval

Monday, February 27, 2012 10:03 AM

The FDA Endocrinologic and Metabolic Drugs Advisory Committee has recommended Vivus’ adult obesity drug Qnexa be granted marketing approval by the FDA.

More... »

Verinata study published in Obstetrics & Gynecology journal

Monday, February 27, 2012 10:01 AM

Obstetrics & Gynecology (Green journal) published full data from Verinata Health’s prospective, blinded, multi-center clinical validation study to detect fetal chromosomal aneuploidies across the entire genome using its verifi prenatal test.

More... »

CenterWatch
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs